Transplant characteristics: Minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia

Leukemia

Volumn 13, Issue 8, 1999, Pages 1227-1234

  Reichle, A ^a   Rothe, G ^b   Krause, S ^b   Zaiss, M ^b   Ullrich, H ^b   Schmitz, G ^b   Andreesen, R ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NONE

Author keywords

Autologous peripheral blood stem cell transplantation; Colony forming units megakaryocytes; De novo AML; Minimal residual disease

Indexed keywords

BUSULFAN; CYTARABINE; DAUNORUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COLONY FORMING UNIT; COLONY FORMING UNIT GM; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; LEUKAPHERESIS; MEGAKARYOCYTE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASIA; PREDICTION; PRIORITY JOURNAL;

EID: 0032868806     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401481     Document Type: Article

References (42)

1. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, Huguet F, Corront B, Cony Makhoul P, Gastaut JA, Laurent G, Molina L, Braustet A, Maraninchi D, Pris J, Hollard D, Faberes C. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10: 1874-1882.
2. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. New Engl J Med 1995; 332: 217-223.
3. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708.
4. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, Lioure B, Lamy T, Desablens B, Guilhot F, Caillot D, Abgrall JF, Francois S, Briere J, Guyotat D, Casassus P, Audhuy B, Tellier Z, Hurteloup P, Herve P. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978-2986.
5. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New Engl J Med 1994; 331: 896-903.
6. McMillan AK, Goldstone AH, Linch DC, Gribben JC, Patterson KG, Richards JD, Franklin I, Boughton BJ, Milligan DW, Leyland MM et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990; 76: 480-488.
7. Reichle A, Hennemann B, Krause S, Meidenbauer N, Zaiss M, Bross KJ, Andreesen R. Peripheral blood stem cell transplantation during postremission treatment of de novo acute myelogenous leukemia. In: Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating M, Plunkett W (eds). Acute Leukemias VII. Springer: Berlin, 1998, pp 915-921.
8. Reichle A, Andreesen R. Myeloablative chemotherapy and peripheral blood stem cell transplantation vs consolidation therapy of acute myelogenous leukemia in first remission. In: Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating M, Plunkett W (eds). Acute Leukemias VII. Springer: Berlin, 1998, pp 922-931.
9. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
10. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez Berges C, Gonzalez M, Caballero D, Garcia Marcos MA, Ramos F, Fernandez Calvo J, Calmuntia MJ, Diaz Mediavilla J, Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470.
11. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, Tricot G. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349-353.
12. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84: 957-963.
13. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535-2542.
14. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833-1844.
15. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation, an additional late complication of curative cancer therapy. Blood 1994; 83: 3780-3786.
16. Pedersen Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
17. Juvonen E, Partanen S, Knuutila S, Ruutu T. Colony formation by megakaryocyte progenitors in myelodysplastic syndromes. Eur J Haematol 1989; 42: 389-395.
18. Geissler D, Zwierzina H, Pechlaner C, Gaggl S, Schmalzl F, Konwalinka G, Braunsteiner H. Abnormal megakaryopoiesis in patients with myelodysplastic syndromes: analysis of cellular and humoral defects. Br J Haematol 1989; 73: 29-35.
19. Dan K, An E, Futaki M, lnokuchi K, Gomi S, Yamada T, Ogata K, Tanabe Y, Ohki I, Shinohara T et al. Megakaryocyte, erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Acta Haematol 1993; 89: 113-118.
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
21. Buchner T, Hiddemann W, Wörmann B, Loffler H, Maschmeyer G, Hossfeld D, Ludwig WD, Nowrousian M, Aul C, Schaefer UW et al. Long-term effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. Leukemia 1992; 6 (Suppl. 2): 68-71.
22. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
23. Berthier R, Valiron O, Schweitzer A, Marguerie G. Serum-free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: role of TGF beta. Stem Cells 1993; 11: 120-129.
24. Zauli G, Vitale L, Brunelli MA, Bagnara GP. Prevalence of the primitive megakaryocyte progenitors (BFU-meg) in adult human peripheral blood. Exp Hematol 1992; 20: 850-854.
25. Goasguen JE, Bennett JM. Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol 1992; 19: 4-13.
26. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland IF. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 454-462.
27. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia 1996; 10: 877-895.
28. + subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 1997; 11: 674-679.
29. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-1434.
30. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW, O'Brien MC, Baron S, Deisseroth AB. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
31. Wörmann B. Implications of detection of minimal residual disease. Curr Opin Oncol 1993; 5: 3-12.
32. Macedo A, Orfao A, Vidriales MB, Lopez Berges MC, Valverde B, Gonzalez M, Caballero MD, Ramos F, Martinez M, Fernandez Calvo J et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995; 70: 189-194.
33. Miyamoto T, Nagafuji K, Harada M, Eto T, Fujisaki T, Kubota A, Akashi K, Mizuno S, Takenaka K, Kanaji T et al. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia. Br J Haematol 1995; 91: 132-138.
34. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437-1438.
35. Muto A, Mori S, Matsushita H, Awaya N, Ueno H, Takayama N, Okamoto S, Kizaki M, Ikeda Y. Serial quantification of minimal residual disease of t(8,21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 1996; 95: 85-94.
36. Gerhartz HH, Schmetzer H. Detection of minimal residual disease in acute myeloid leukemia. Leukemia 1990; 2: 508-516.
37. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD, Jones RJ. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991; 78: 1125-1131.
38. del Canizo MC, Mota A, Orfao A, Galende J, Caballero MD, Garcia Marcos MA, San Miguel JF. Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia. J Clin Pathol 1996; 49: 450-452.
39. Gale RE, Bunch C, Moir DJ, Patterson KG, Goldstone AH, Linch DC. Demonstration of developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high-dose chemotherapy and autologous bone marrow transplantation using X-chromosome inactivation patterns. Br J Haematol 1996; 93: 53-58.
40. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, Neglia JP. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
41. Legare RD, Gribben JG, Maragh M, Hermanowski Vosatka A, Roach S, Tantravahi R, Nadler LM, Gilliland DG. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am J Hematol 1997; 56: 45-51.
42. Domenech J, Linassier C, Gihana E, Dayan A, Truglio D, Bout M, Petitdidier C, Delain M, Petit A, Bremond JL et al. Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation. Blood 1995; 85: 3320-3327.